Teva to halt Phase II MSA therapy trial after futility analysis

​

Teva Pharmaceuticals has announced plans to halt a Phase II clinical trial evaluating emrusolmin (TEV-'286) to treat adults with MSA, after an interim analysis found the study was unlikely to meet its primary efficacy endpoint.

The post Teva to halt Phase II MSA therapy trial after futility analysis appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.